Tactile Systems Technology Reports 23% Revenue Growth to $75.3 Million in Q1 2026

Tactile Systems Technology, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $75.3 million, a 23% increase from $61.3 million in the same period last year. The growth was primarily driven by a 28% rise in sales revenue from lymphedema products, which accounted for 83% of total revenue, and a 22% increase in sales of airway clearance products. Despite the revenue growth, the company recorded a net loss of $1.8 million, an improvement from the $3.0 million loss reported in the prior year.

The company's cost of revenue also increased, rising 11% to $17.7 million, which was in line with the revenue growth. Gross profit improved to $57.6 million, reflecting a gross margin of 77%, up from 74% in the previous year. Operating expenses increased by 19% to $59.1 million, driven by higher sales and marketing costs, research and development expenses, and general administrative costs, including expenses related to the recent acquisition of LymphaTech, Inc.

In terms of strategic developments, Tactile Systems completed the acquisition of LymphaTech on February 17, 2026, for approximately $7.2 million, which is expected to enhance its offerings in the lymphedema treatment space. The acquisition is part of the company's strategy to expand its product portfolio and improve patient outcomes through innovative technology. As of March 31, 2026, the company employed 172 account managers and 163 specialists for its lymphedema products, an increase from the previous year, indicating a focus on strengthening its sales force.

Operationally, Tactile Systems reported a decrease in cash to $75.0 million from $83.6 million a year earlier, alongside a net accounts receivable increase to $38.2 million. The company experienced a net cash outflow from operating activities of $0.3 million, compared to a positive cash flow of $0.4 million in the prior year. The cash used in investing activities was primarily related to the LymphaTech acquisition, totaling $7.1 million. The company also repurchased 40,250 shares for approximately $1.1 million during the quarter, as part of its ongoing share repurchase program.

Looking ahead, Tactile Systems anticipates continued growth driven by its strategic initiatives and product offerings. The company remains focused on enhancing its commercial infrastructure and expanding its market presence, while also navigating potential challenges such as inflation and competitive pressures. The management believes that its current cash reserves and operational cash flows will be sufficient to meet its working capital and investment needs for at least the next twelve months.